Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril

Stem Cells

Volumn 15, Issue 6, 1997, Pages 455-460

  Chisi, J E ^a   Wdzieczak Bakala, J ^b   Riches, A C ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b CNRS   (France)

Author keywords

AcSDKP; Angiotensin I converting enzyme (ACE); Captopril; Hematopoietic stem cells; Irradiation; Lisinopril

Indexed keywords

CAPTOPRIL; COLONY STIMULATING FACTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 3; LISINOPRIL; TETRAPEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELL CYCLE; CELL PROLIFERATION; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME ACTIVE SITE; FEMALE; GAMMA IRRADIATION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION;

ANIMALIA; MURINAE;

EID: 0030815755     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150455     Document Type: Article

References (33)

1. Ali AM, Wright EG, Riches AC. Local regulation of haematopoietic stem cell proliferation in mice following irradiation. Cell Tissue Kinet 1989;22:333-341.
2. Tubiana M, Carde P, Frindel E, Ways of minimising hematopoietic damage induced by irradiation and cytotoxic drugs - the possible role of inhibitors. Radiother Oncol 1993;29:1-17.
3. Dunlop DJ, Wright EG, Lorimore S et al. Demonstration of stem cell inhibition and myeloprotective effect of SCI/rhMIP1α in vivo. Blood 1992;79:2221-2225.
4. Coutinho LH, Testa NG, Dexter TM. The myelosuppressive effects of recombinant interferon γ in short-term and long-term marrow cultures. Br J Haematol 1986;63:517-524.
5. Lotem J, Sachs L. Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor β1 in normal and leukemic myeloid cells. Blood 1990;76:1315-1322.
6. Lenfant M, Wdzieczac-Bakala J, Guittet E et al. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 1989;86:779-782.
7. Bonnet D, Cesaire R, Lemoine F et al. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Exp Hematol 1992;20:251-255.
8. Wdzieczak-Bakala J, Fache M-P, Lenfant M et al. AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture. Leukemia 1990;4:235-237.
9. Robinson S, Lenfant M, Wdzieczak-Bakala J et al. The molecular specificity of action of the tetrapeptide Acetyl-N-Ser-Asp-Pro (AcSDKP) in the control of hematopoietic stem cell proliferation. STEM CELLS 1993;11:422-427.
10. Monpezat J-P, Frindel E. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP-1. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response. Exp Hematol 1989;17:1077-1080.
11. Lenfant M, Itoh K, Sakoda H et al. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by the tetrapetide Acetyl-N-Ser-Asp-Lys-Pro. Exp Hematol 1989;17:898-902.
12. Bogden AE, Carde P, Deschamps de Paillette E et al. Amelioration of chemotherapy induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann NY Acad Science 1991;628:126-139.
13. Wierenga PK, Konings WT. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitor and stem cells against hyperthermic damage. Exp Hematol 1996;24:246-252.
14. Coutton C, Guigon M, Bohbot A et al. Photoprotection of normal human hematopoietic progenitors by the tetrapeptide N-AcSDKP. Exp Hematol 1994;22:1076-1080.
15. Watanabe T, Kelsey LS, Yan Y et al. In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. Br J Haematol 1996;94:619-627.
16. Li J, Volkov L, Comte L et al. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp Hematol 1997;25:140-146.
17. Grillon C, Rieger K, Bakala J et al. Involvement of thymosin b4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro, a regulator of the hematopoietic system. FEBS Lett 1990;274:30-34.
18. Bonnet D, Lemoine FM, Frobert Y et al. Thymosin b4, inhibitor for normal hematopoietic progenitor cells. Exp Hematol 1996;24:776-782.
19. Rieger K-J, Saez-servent N, Papet M-P et al. Involvement of human plasma angiotensin 1-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J 1993;296:373-378.
20. Wei L, Clauser E, Alhenc-Gelas F et al. The two homologous domains of human angiotensin 1-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992;267:13398-13405.
21. Rousseau A, Michaud A, Chauvet M-T et al. The hemoregulatory peptide N-acetyl-ser-asp-lys-pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995;270:3656-3661.
22. Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest 1996;97:839-844.
23. Kriegler AB, Verschoor SM, Bemardo D et al. The relationship between different high proliferative potential colony-forming cells in mouse bone marrow. Exp Hematol 1994;22:432-440.
24. Grillon C, Lenfant M, Wdzieczak-Bakala J. Optimization of cell culture conditions for the evaluation of the biological activities of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro, a natural hemoregulatory factor. Growth Factors 1993;9:1-8.
25. Millard RE, Okell SF. The effect of cytosine arabinoside in vitro on agar colony forming cells and spleen colony forming cells of C57BL mouse bone marrow. Cell Tissue Kinet 1975;8:33-40.
26. Bol S, Van Den Engh G, Visser J. A technique for staining haemopoietic colonies in agar cultures. Exp Hematol 1977;5:551-663.
27. Rousseau-Plasse A, Lenfant M, Potier P. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-1-converting enzyme N-active site. Bioorg Med Chem 1996;4:1113-1119.
28. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1523.
29. Johnston CL, Arnold L, Hiwatari M. Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs 1984;27:271-277.
30. Schindler R, Dinarello CA, Koch K-M. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995;7:526-533.
31. Bertoncello I, Bradley TR, Hodgson GS. The concentration and resolution of primitive hematopoietic cells from normal bone marrow by negative selection using monoclonal antibodies and dynabead monodisperse magnetic microspheres. Exp Hematol 1989;17:171-176.
32. Guigon M, Mary J-Y, Enouf J et al. Protection of mice against lethal doses of 1β-D-Arabinofuranosylcytosine by pluripotent stem cell inhibitors. Cancer Res 1982;42:638-641.
33. Volkov L, Quere P, Coudert F et al. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines. Exp Cell Res 1996;223:112-116.